Study compares oclacitinib and CCNU in canine T-cell lymphoma
Bottom line
A small retrospective study in Veterinary Dermatology suggests oclacitinib may offer outcomes comparable to lomustine (CCNU) for dogs with canine epitheliotropic T-cell lymphoma, while requiring less intensive monitoring and causing fewer adverse effects. The paper reviewed 23 dogs and found similar survival, tumour reduction, and relapse outcomes between the two treatment groups, according to the journal abstract provided in the source material. That finding matters because CCNU has long been used in this setting, but historical data show it can require dose reductions for neutropenia, thrombocytopenia, anemia, and liver enzyme increases. (academic.oup.com)
Why it matters: For veterinary teams, the signal here isn't that oclacitinib is ready to replace standard oncology protocols across the board, but that it may deserve consideration as a lower-burden option in selected cases, especially when monitoring intensity, tolerability, or pet parent adherence are concerns. Interest in oclacitinib for this disease has been building through case reports and small retrospective series, including a 2021 case report, a 2024 Japanese case report describing more than a year of disease control without reported side effects, and a 2025 retrospective study of eight dogs that characterized efficacy as limited overall. Oclacitinib's use here is also notable because the drug's label advises clinicians to weigh risks and benefits in dogs with neoplasia, and safety information notes new neoplastic conditions have been observed in clinical and post-approval experience. (onlinelibrary.wiley.com)
What to watch: The next step is whether the authors publish full outcome data and whether larger prospective studies can clarify which CETL cases, if any, benefit most from oclacitinib-based treatment. (academic.oup.com)
Key facts
- Study type
- Retrospective comparison
- Journal
- Veterinary Dermatology
- Sample size
- 23 dogs
- Condition
- Canine epitheliotropic T-cell lymphoma
- Treatments compared
- Oclacitinib and lomustine (CCNU)
- Main finding
- Comparable survival, tumour reduction, and relapse outcomes
- Safety finding
- Oclacitinib had fewer adverse effects and less intensive monitoring
- Context
- CCNU has long been used in this setting, but standard treatment is not clearly established
A retrospective study in Veterinary Dermatology is adding to the small but growing body of evidence around oclacitinib for canine epitheliotropic T-cell lymphoma, a rare and difficult-to-manage cutaneous malignancy. In 23 dogs treated with either oclacitinib or lomustine (CCNU), the study found comparable survival, tumour reduction, and relapse outcomes, with oclacitinib associated with fewer adverse effects and less intensive monitoring, based on the journal abstract supplied in the source material. (academic.oup.com)
That matters because CCNU has been one of the better-known systemic options in this disease for years, despite the absence of a clear standard of care. In a 46-dog retrospective study published in 2006, CCNU produced an 83% overall response rate, but the median duration of response was 94 days, and dose reductions were commonly needed because of hematologic or hepatic adverse events. The same paper described canine cutaneous epitheliotropic lymphoma as an uncommon T-cell malignancy and explicitly noted that consensus on standard treatment was lacking. (academic.oup.com)
More recent literature has kept interest alive in JAK inhibition as a possible alternative or adjunct. A 2021 Veterinary Dermatology case report documented oclacitinib treatment in canine cutaneous epitheliotropic T-cell lymphoma, and a 2024 Japanese case report described a dog with paw lesions that improved after switching to oclacitinib on day 204, with reported continued control for more than one year and no side effects. At the same time, a 2025 retrospective study of eight dogs concluded that oral oclacitinib had limited efficacy overall, underscoring how preliminary and mixed the evidence base still is. (onlinelibrary.wiley.com)
The new 23-dog comparison is therefore less a definitive practice-changing trial than an important signal in a disease area where clinicians often work with sparse data. Based on the abstract, the headline finding is not superior efficacy, but similar clinical outcomes with a potentially easier safety and monitoring profile. For general practitioners and specialists alike, that's relevant because CETL cases often involve chronic skin lesions, repeated rechecks, and difficult quality-of-life conversations with pet parents. A treatment that performs similarly while reducing monitoring burden could change how some teams frame options, especially when referral access, cost, or tolerance of chemotherapy are limiting factors. That said, this remains retrospective evidence, and the small sample size sharply limits confidence in broad conclusions. (academic.oup.com)
There is also an important safety and regulatory nuance. Oclacitinib is widely used for pruritus and atopic dermatitis, not oncology, and its labeling does not position it as an antineoplastic therapy. FDA safety-related labeling changes state clinicians should consider risks and benefits before initiating Apoquel in dogs with neoplasms, while Zoetis safety information says new neoplastic conditions, both benign and malignant, were observed in clinical studies and post-approval experience. In other words, any use in CETL is off-label and sits in a clinically complicated space where the patient already has cancer. (fda.gov)
Why it matters: For veterinary professionals, the practical value of this study is that it may widen the conversation around individualized CETL management rather than settle it. If oclacitinib can deliver similar control with fewer adverse effects in some dogs, it could become a more credible option for cases where CCNU monitoring is difficult, where prior chemotherapy toxicity is a concern, or where pet parent goals center more heavily on comfort and manageable follow-up. But the mixed literature also argues for caution: a positive case report, a small favorable comparison, and a separate small study suggesting limited efficacy can all be true at once in a heterogeneous disease with varied presentations and stages. (jstage.jst.go.jp)
What to watch: The key next step is publication of fuller data beyond the abstract, including response definitions, survival intervals, adverse-event details, dosing, concurrent therapies, and case selection. After that, the field will need larger prospective studies, or at least multi-center retrospective datasets, to identify whether particular CETL phenotypes are more likely to benefit from oclacitinib and how it should be positioned relative to CCNU, radiation, retinoids, corticosteroids, or combination approaches. (academic.oup.com)